Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN)

Liver International

Volumn 35, Issue 5, 2015, Pages 1623-1632

  Hayashi, Paul H ^a   Barnhart, Huiman X ^b   Fontana, Robert J ^c   Chalasani, Naga ^d   Davern, Timothy J ^e   Talwalkar, Jayant A ^f   Reddy, K Rajender ^g   Stolz, Andrew A ^h   Hoofnagle, Jay H ⁱ   Rockey, Don C ^j  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

Adverse reaction; Diagnosis; Drug induced liver injury; Hepatotoxicity; Toxicity

Indexed keywords

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; DIET SUPPLEMENTATION; DRUG EXPOSURE; FEMALE; FOLLOW UP; HUMAN; INTERRATER RELIABILITY; KAPPA STATISTICS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TEST RETEST RELIABILITY; TOXIC HEPATITIS; UNCERTAINTY; ADVERSE EFFECTS; AGED; CHEMICAL AND DRUG INDUCED LIVER INJURY; COHORT ANALYSIS; DIETARY SUPPLEMENT; REPRODUCIBILITY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; VALIDATION STUDY;

PLANT MEDICINAL PRODUCT;

ADULT; AGED; CHEMICAL AND DRUG INDUCED LIVER INJURY; COHORT STUDIES; DIETARY SUPPLEMENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLANT PREPARATIONS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84995332299     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12540     Document Type: Article

References (21)

1. Hoofnagle JH. Drug-induced liver injury network (DILIN). Hepatology 2004; 40: 773.
2. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-30.
3. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-6.
4. Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26: 664-9.
5. Rochon J, Protiva P, Seeff LB, et al. Reliability of the Roussel Uclaf causality assessment method for assessing causality in drug-induced liver injury. Hepatology 2008; 48: 1175-83.
6. Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009; 32: 55-68.
7. Agarwal VK, McHutchison JG, Hoofnagle JH. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010; 8: 463-70.
8. Davern TJ, Chalasani N, Fontana RJ, et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011; 141: 1665-72. e1-9.
9. Garcia-Cortes M, Stephens C, Lucena MI, Fernandez-Castaner A, Andrade RJ. Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol 2011; 55: 683-91.
10. Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41: 257-64.
11. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
12. Dalton HR, Fellows HJ, Stableforth W, et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther 2007; 26: 1429-35.
13. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34, 34 e1-4.
14. Zimmerman HJ. Antituberculosis agents. In: Zimmerman HJ, ed. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver, 2nd edn. Philadelphia: Lipponcott Williams & Wilkins, 1999; 611-21.
15. Lucena MI, Andrade RJ, Fernandez MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 2006; 44: 850-6.
16. Verma S, Kaplowitz N. Hepatotoxicity of antituberculosis drugs. In: Kaplowitz N, DeLeve LD, eds. Drug-Induced Liver Disease, 2nd edn. New York: Informa Healthcare USA, 2007; 547-66.
17. Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ 1999; 319: 1541.
18. Teschke R, Schulze J, Schwarzenboeck A, Eickhoff A, Frenzel C. Herbal hepatotoxicity: suspected cases assessed for alternative causes. Eur J Gastroenterol Hepatol 2013; 25: 1093-8.
19. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-76.
20. Agarwal VK, McHutchison JG, Hoofnagle JH. Important elements for the diagnosis of Drug-Induced Liver Injury. Clin Gastroenterol Hepatol 2010; 8: 463-70.
21. Teschke R, Eickhoff A, Schulze J. Drug- and herb-induced liver injury in clinical and translational hepatology: causality assessment methods, quo vadis? J Clin Translat Hepatol 2013; 1: 59-74.